FDA approved zidesamtinib for previously treated ROS1+ locally advanced/metastatic NSCLC, marking GSK’s entry into approved lung cancer therapeutics following acquisition of Nuvalent’s portfolio. ROS1 ...
Zidesamtinib targets ROS1-positive NSCLC, showing promise in overcoming resistance mutations and CNS metastases with brain penetrance. The ARROS-1 trial demonstrated significant response rates in TKI ...
Drugs like crizotinib are used to treat patients with ROS1-positive lung cancer. But which patients are ROS1-positive? A University of Colorado Cancer Center study published in the Journal of Thoracic ...
ROS1-positive non-small cell lung cancer (NSCLC) is a rare lung cancer subtype occurring when part of the ROS1 gene fuses with another gene. Affecting around 1% to 2% of people with NSCLC, it tends to ...
ROS1-positive non-small cell lung cancer (NSCLC) is a rare subtype of lung cancer that occurs when part of the ROS1 gene fuses with another gene. It affects about 1% to 2% of people with NSCLC and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results